|
Pharmexcil to discuss key issues related to exports with Saudi Arabia for potential collaborations
|
|
Shardul Nautiyal, Mumbai
August 06 , 2025
|
|
|
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has invited its member companies to report and discuss key issues related to exports with Saudi Food and Drug Authority (SFDA) to further potential business collaborations.
A virtual meeting with the SFDA is scheduled on August 6, 2025 to discuss the same. Following this, the Kingdom of Saudi Arabia (KSA) will also be hosting a webinar on August 18 to reach out to Indian pharmaceutical and medical device companies for strategic partnerships and investment in its rapidly expanding healthcare sector.
These discussions are a part of Saudi Arabia’s broader vision to localize healthcare manufacturing, enhance supply chain resilience, and attract foreign investment under its Vision 2030 framework.
Pharmexcil has also compiled inputs from the pharmaceutical industry regarding issues faced with the SFDA. Concerns or observations to be discussed will be related to product registration or renewal with SFDA, regulatory or technical requirements, pricing-related issues, inspection or audit-related concerns, import permissions or delays, communication or coordination with SFDA and any other matter impacting exports to Saudi Arabia.
“The discussions are aimed to help Indian exporters to understand and further collaborate with Saudi Arabia’s evolving healthcare ecosystem and explore prospects for joint ventures, technology transfer, and investment,” according to Pharmexcil director general (DG) K Raja Bhanu.
Strategic benefits of these collaborations will lead to national drug security by reducing reliance on imports, expansion of local industrial base and pharmaceutical ecosystem and create high-value jobs and encourage knowledge transfer.
Key growth drivers for these collaborations and opportunities are increasing demand for chronic disease management, government incentives and regulatory support for localization, strong potential for regional exports and strategic partnerships with global pharmaceutical players.
These opportunities aim to localize the manufacturing of active pharmaceutical ingredients (APIs). The initiative supports national health security and aims to reduce dependency on imports while supporting Saudi Arabia’s growing pharmaceutical manufacturing capabilities.
Saudi Arabia also seeks to localize the production of key starting materials (KSMs) as a part of foundational investment that strengthens the upstream pharmaceutical supply chain, reduces dependency on imports, and contributes to long-term national health security.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|